About – BrainSee

How BrainSee Works

3 step Instructions

Step 1

Input patient data

Step 2

Request analysis

Step 3

Get the report the same day

Background information about MCI, Alzheimer's disease and Alzheimer’s dementia;

how BrainSee fits into the whole picture, and how BrainSee is going to make a difference;

We know that pathologically Alzheimer’s disease starts in the brain long before the onset of dementia, and can pass through a mild cognitive impairment stage on its way to dementia stage. A mild cognitive impairment is a gray zone, which is not cognitively healthy and not full blown dementia.

Amnestic Mild cognitive impairment (aMCI) is referred to a type of MCI where memory loss is an outstanding concern. aMCI is a condition that can be caused by Alzheimer’s disease, normal aging, or other neurological conditions. More than 30% of aMCI will stay stable or even improve in time and therefore will never get to the dementia stage. These aMCI do not have Alzheimer’s disease and their condition is caused by other factors.

Today, it’s not possible to differentiate aMCI-caused by Alzheimer’s disease, and therefore converter to dementia in the future from aMCI-not caused by Alzheimer’s disease and therefore non-converter to dementia in the future. BrainSee helps doctors with such a differentiation (prognosis of aMCI).

Early detection of Alzheimer’s disease, enabled by BrainSee, can help postpone dementia through:

early interventions (medications and lifestyle modifications)
management of comorbidities

Early identification of Alzheimer’s disease also enables patients and their families to make practical plans for their upcoming legal and financial needs and determine best opportunities for care options.

BrainSee’s score is dynamic and patient-specific. Changes in such a granular quantitative measure of the brain can help doctors find the best course of interventions for their patients. It can also be used in clinical trial studies that aim to prevent/ postpone dementia.